Protease activated receptors in cardiovascular function and disease

被引:28
作者
Barnes, JA [1 ]
Singh, S
Gomes, AV
机构
[1] Univ W Indies, Fac Med Sci, Biochem Unit, St Augustine, Trinidad Tobago
[2] Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA
关键词
protease activated receptor; cardiovascular disease; thrombin;
D O I
10.1023/B:MCBI.0000041864.14092.5b
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Recent studies have shown that a novel class of protease activated receptors (PARs), which are composed of seven transmembrane G protein-coupled domains, are activated by serine proteases such as thrombin, trypsin and tryptase. Although four types ( PAR 1, PAR 2, PAR 3 and PAR 4) of this class of receptors have been identified, their discrete physiological and pathological roles are still being unraveled. Extracellular proteolytic activation of PARs results in the cleavage of specific sites in the extracellular domain and formation of a new N-terminus which functions as a tethered ligand. The newly formed tethered ligand binds intramolecularly to an exposed site in the second transmembrane loop and triggers G-protein binding and intracellular signaling. Recent studies have shown that PAR-1, PAR-2 and PAR-4 have been involved in vascular development and a variety of other biological processes including apoptosis and remodeling. The use of animal model systems, mainly transgenic mice and synthetic tethered ligand domains, have contributed enormously to our knowledge of molecular signaling and the regulatory properties of various PARs in cardiomyocytes. This review focuses on the role of PARs in cardiovascular function and disease.
引用
收藏
页码:227 / 239
页数:13
相关论文
共 131 条
[51]  
Hollenberg MD, 1996, MOL PHARMACOL, V49, P229
[52]   Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides [J].
Hollenberg, MD ;
Saifeddine, M ;
AlAni, B ;
Kawabata, A .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1997, 75 (07) :832-841
[53]  
HUNG DT, 1992, J BIOL CHEM, V267, P20831
[54]   Evidence for the presence of a proteinase-activated receptor distinct from the thrombin receptor in vascular endothelial cells [J].
Hwa, JJ ;
Ghibaudi, L ;
Williams, P ;
Chintala, M ;
Zhang, RM ;
Chatterjee, M ;
Sybertz, E .
CIRCULATION RESEARCH, 1996, 78 (04) :581-588
[55]   Protease-activated receptor 3 is a second thrombin receptor in humans [J].
Ishihara, H ;
Connolly, AJ ;
Zeng, DW ;
Kahn, ML ;
Zheng, YW ;
Timmons, C ;
Tram, T ;
Coughlin, SR .
NATURE, 1997, 386 (6624) :502-506
[56]   Thrombin receptor actions in neonatal rat ventricular myocytes [J].
Jiang, TR ;
Kuznetsov, V ;
Pak, E ;
Zhang, HL ;
Robinson, RB ;
Steinberg, SF .
CIRCULATION RESEARCH, 1996, 78 (04) :553-563
[57]   Gene and locus structure and chromosomal localization of the protease-activated receptor gene family [J].
Kahn, ML ;
Hammes, SR ;
Botka, C ;
Coughlin, SR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (36) :23290-23296
[58]   Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin [J].
Kahn, ML ;
Nakanishi-Matsui, M ;
Shapiro, MJ ;
Ishihara, H ;
Coughlin, SR .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (06) :879-887
[59]   A dual thrombin receptor system for platelet activation [J].
Kahn, ML ;
Zheng, YW ;
Huang, W ;
Bigornia, V ;
Zeng, DW ;
Moff, S ;
Farese, RV ;
Tam, C ;
Coughlin, SR .
NATURE, 1998, 394 (6694) :690-694
[60]   In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist [J].
Kato, Y ;
Kita, Y ;
Nishio, M ;
Hirasawa, Y ;
Ito, K ;
Yamanaka, T ;
Motoyama, Y ;
Seki, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 384 (2-3) :197-202